Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 May;37(5):997–1000. doi: 10.1128/aac.37.5.997

In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.

I Brook 1
PMCID: PMC187875  PMID: 8517727

Abstract

Therapy with ofloxacin, ciprofloxacin, and lomefloxacin (alone or in combination with clindamycin) and therapy with sparfloxacin, clinafloxacin, and temafloxacin alone were given to mice with subcutaneous abscesses. The abscesses were caused by two Bacteroides fragilis isolates, one of which was susceptible and one of which was resistant to ofloxacin, ciprofloxacin, and lomefloxacin, alone or in combination with Escherichia coli. The abscesses were examined 5 days after inoculation. Numbers of B. fragilis organisms reached log10 10.2 to 11.8 per abscess, and numbers of E. coli organisms reached log10 10.6 to 11.8 per abscess. All of the quinolones reduced the number of susceptible B. fragilis isolates (log10 3.6 to 6.9) and E. coli isolates (log10 5.7 to 6.8). However, ciprofloxacin and lomefloxacin failed to reduce the number of resistant B. fragilis organisms in single-organism or mixed infections. The addition of clindamycin to either ofloxacin, ciprofloxacin, or lomefloxacin reduced the numbers of both susceptible and resistant B. fragilis organisms (log10 3.8 to 7.8). In contrast, sparfloxacin, clinafloxacin, and temafloxacin were effective as single therapy in eradicating B. fragilis resistant to ofloxacin, ciprofloxacin, and lomefloxacin. These in vivo data confirm the in vitro activity of these quinolones and suggest that although ofloxacin, ciprofloxacin, and lomefloxacin are occasionally effective as single agents in eradicating mixed infection by susceptible strains of B. fragilis and E. coli, addition of an agent with activity against anaerobic organisms will ensure their efficacy. Quinolones with good efficacy against B. fragilis may be effective as single-agent therapy of mixed infections.

Full text

PDF
997

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chin N. X., Figueredo V. M., Novelli A., Neu H. C. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):58–63. doi: 10.1007/BF01962176. [DOI] [PubMed] [Google Scholar]
  2. Goldstein E. J., Citron D. M. Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole. Antimicrob Agents Chemother. 1991 Nov;35(11):2447–2449. doi: 10.1128/aac.35.11.2447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kasper D. L. The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis. 1976 Jan;133(1):79–87. doi: 10.1093/infdis/133.1.79. [DOI] [PubMed] [Google Scholar]
  4. Solomkin J. S., Fant W. K., Rivera J. O., Alexander J. W. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med. 1985 Jun 7;78(6A):85–91. doi: 10.1016/0002-9343(85)90106-8. [DOI] [PubMed] [Google Scholar]
  5. Wexler H. M., Molitoris E., Finegold S. M. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother. 1992 Jan;36(1):239–243. doi: 10.1128/aac.36.1.239. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES